CEL-SCI closes $10.8M public offering of common stock and pre-funded warrants

CEL SCI CORP

Gross proceeds of $10,845,000 from offering of 10,845,000 shares/common stock or pre-funded warrants at $1.00/share.
Net proceeds to fund continued development of lead cancer drug Multikine and for general corporate purposes.
Offering closed on July 29, 2024; ThinkEquity acted as sole placement agent.
Officers and directors subject to 90-day lock-up on company securities.
Pre-funded warrants exercisable at $0.01 per share and expire when fully exercised.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.